NCT07199894 Omegapres Versus Solifenacin and Mirabegron Combination Therapy in Treatment of Primary MNE
| NCT ID | NCT07199894 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Mansoura University |
| Condition | Nocturnal Enuresis in Children |
| Study Type | INTERVENTIONAL |
| Enrollment | 120 participants |
| Start Date | 2024-12-01 |
| Primary Completion | 2025-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 120 participants in total. It began in 2024-12-01 with a primary completion date of 2025-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to compare combination of Solifenacin and MIrabegron in treatment of primary mono-symptomatic nocturnal enuresis in children. It will also learn about the safety of that combination. The main questions it aims to answer are: Does combination of Solifenacin and MIrabegron lower the number of wet nights? What medical problems do participants have when taking combination of Solifenacin and MIrabegron? Researchers will compare the combination to omegapress to see if the combination works better to treat primary mono-symptomatic nocturnal enuresis. Participants will: Take the combination or Omegapress every day for 3 months Visit the clinic once monthly for checkups and tests Keep a diary of their symptoms and the number of wet nights
Eligibility Criteria
Inclusion Criteria: Primary mono-symptomatic nocturnal enuresis - Exclusion Criteria: Bowel dysfunction Psychatric illness Respiratory sleep disorders \-
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07199894 clinical trial?
This trial is open to participants of all sexes, aged 6 Years or older, up to 18 Years, studying Nocturnal Enuresis in Children. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07199894 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 120 participants.
Is NCT07199894 currently recruiting?
Yes, NCT07199894 is actively recruiting participants. Contact the research team at hameedshahin95@gmail.com for enrollment information.
Where is the NCT07199894 trial being conducted?
This trial is being conducted at Al Mansurah, Egypt.
Who is sponsoring the NCT07199894 clinical trial?
NCT07199894 is sponsored by Mansoura University. The trial plans to enroll 120 participants.